| 摘要 |
The invention is directed to sodium channel blockers consisting of pyrazinoylguanidine compounds of the formula (I): (see formula I) These compounds give a prolonged pharmacodynamic half-life on mucosal surfaces and make them particularly useful for treating cardiovascular disease. |
